Printer Friendly

COMPANY INFORMATION
Kane Biotech Inc. 5-1250 Waverley St Winnipeg, MB R3T 6C6 Tel: (204) 453-1301 Fax: (204) 453-1314 Contact Name Investor Relations Industry Biotechnology		Key Executives Gord Froehlich, CEO Eric R. Johnstone, CFO Researches and develops products to prevent and disperse bacterial biofilms based on molecular mechanisms of biofilm formation, for potential use in medical and industrial applications. Products under development target health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
FP ADVISOR COVERAGE Kane Biotech Inc. • FP Corporate Surveys • FP Directory of Directors • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/KNE $0.16 $0.21 $0.06 n.a. n.a. n.a. 1.06 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 37,602 n.a. $-0.03 June 30/09 146.15% -26.32% -25.13% $4,608
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 $000s $000s $000s Net income (1,077) (1,090) (956) Total assets 1,572 1,229 1,518 $ $ $ Earnings per share* (0.04) (0.06) (0.06) % % % Return on equity (81.78) (84.96) (78.30)   * Common

COMPANY NEWS

Results for 'Kane Biotech Inc.' from past 30 days: No hits. (Links are to articles.)